Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 18, 2025 | $0.06 | 2025-08-15 | 2025-08-15 |
| June 5, 2025 | $0.12 | 2025-04-25 | 2025-04-25 |
| September 19, 2024 | $0.05 | 2024-08-16 | 2024-08-16 |
| May 16, 2024 | $0.11 | 2024-03-14 | 2024-03-15 |
| October 5, 2023 | $0.04 | 2023-08-24 | 2023-08-25 |
Dividends Summary
- Haleon plc American Depositary Shares (Each representing two Ordinary Shares) has issued 6 dividend payments over the past 2 years
- The most recent dividend was paid 2 days ago, on September 18, 2025
- The highest dividend payed out to investors during this period was $0.12459 per share
- The average dividend paid during this period was $0.07 per share.
Company News
Pfizer has sold its remaining 7.3% stake in Haleon for $3.1 billion, fully exiting its position in the company. Haleon expects 2025 organic revenue growth of 4% to 6%, with stronger performance in the second half.
The global pediatric oral care market is expected to grow significantly due to rising awareness of early oral hygiene and increasing prevalence of dental issues in children. Demand for specialized products, including toothbrushes, toothpaste, and dental floss, is driving market expansion.
Pfizer's COVID-19 products continue to generate significant cash flow, helping bolster the company's dividend. Pfizer's ability to monetize assets and its new product pipeline also contribute to the safety of its ultra-high-yield dividend.
Pfizer's stock has fallen over 60% since its peak during the pandemic, but the company is showing signs of recovery with revenue growth and a robust drug pipeline. The stock is trading at a value with a high dividend yield, making it an attractive investment opportunity.
GSK has a diversified business with a strong vaccines portfolio and promising new products in its pipeline. The spin-off of its consumer healthcare unit has allowed it to focus on drug development. While facing some challenges, GSK's growth potential and attractive valuation make it a compelling investment option.